TriSalus Life Sciences (TLSI) announced updates to its executive leadership team. James Young, who previously served as the company’s senior VP of investor relations and treasurer, has been appointed as the company’s CFO. In this role, Young succeeds Sean Murphy, who will continue to serve the company as chief manufacturing, strategy and business development officer and as a member of the board of directors. The company also promoted Richard Marshak to chief commercial officer and Jodi Devlin to chief of clinical strategy and operations. All appointments were effective as of January 6.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI:
- TriSalus Life Sciences initiated with an Overweight at Cantor Fitzgerald
- TriSalus Life Sciences management to meet with Maxim
- TriSalus Life Sciences price target lowered to $11 from $12 at Canaccord
- TriSalus Life Sciences Reports Strong Q3 Growth
- TriSalus Life Sciences reports Q3 EPS (12c), consensus (37c)